BBA
TPST icon

Baker Bros. Advisors’s Tempest Therapeutics TPST Stock Holding History

Baker Bros. Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,274
Closed -$4.4M – 118
2020
Q1 		$4.4M Hold
4,274
– – 0.03% 67
2019
Q4 		$5.62M Buy
+4,274
New +$6.03M 0.03% 67

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Baker Bros. Advisors's TPST Position: Q2 2020 in Review

Baker Bros. Advisors sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 4,274 shares — an estimated $4.4M sold.

Baker Bros. Advisors first reported a position in TPST in Q4 2019 and held it in 2 quarters. The position peaked at $5.62M in Q4 2019. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

  • Baker Bros. Advisors reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 4,274 Tempest Therapeutics shares in Q2 2020, an estimated $4.4M.
  • Baker Bros. Advisors first reported a position in Tempest Therapeutics in Q4 2019 and held it in 2 quarters.
  • Baker Bros. Advisors's Tempest Therapeutics position peaked at $5.62M in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.